Dr. Hain is currently director of scientific operations at Melior Discovery, Inc., where she manages drug development efforts for Melior, as well as partner companies, using unique in vivo screening systems. Dr. Hain was previously a senior cientist at Xenogen Biosciences in Cranbury, New Jersey. There she supervised CNS and pain assays for the phenotyping group and assisted in establishing Xenogen's internal phenotyping program. From 1999 to 2001, Dr. Hain was a postdoctoral fellow in the CNS group at Pfizer in Ann Arbor, Michigan. There she worked on developing a high-throughput drug screen assay for operant behavior in pre-clinical models. Dr. Hain received her PhD in behavioral neuroscience in 1999 from Oregon Health Sciences University. She is a member of the Society for Neuroscience and the International Behavioral and Neural Genetics Society.